New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOrforglipron vs IGF-1 LR3

Orforglipron vs IGF-1 LR3

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Orforglipron
Anabolic & IGF
IGF-1 LR3
Summary
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
Half-Life
~12 hours (once-daily oral dosing)
20–30 hours
Admin Route
Oral
SubQ, IM
Research
Typical Dose
12 mg → 24 mg → 36 mg → 45 mg
40–80 mcg
Frequency
Once daily
Once daily or split twice daily
Key Benefits
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
  • Direct muscle hypertrophy via IGF-1R stimulation
  • Muscle hyperplasia (new fiber formation) — unique among peptides
  • Rapid gains in lean muscle mass
  • Accelerated recovery from training and injury
  • Increased nutrient uptake by muscle cells
  • Fat oxidation enhancement
  • Bone density improvement
  • Cartilage and connective tissue repair
Side Effects
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
  • Hypoglycemia (significant risk — insulin-like activity)
  • Acromegaly-like effects with excessive long-term use
  • Jaw and hand swelling
  • Organ hypertrophy with extreme doses
  • +2 more
Stacks With